Table 2. Expression of senescence markers in total cohort (n=155) and according to tumoral SS status.
| Senescence marker | Range | Median | Mean ± SD | High expression, n (%) | Low expression, n (%) | Negative expression, n (%) |
|---|---|---|---|---|---|---|
| % Lipofuscin + cells | 0–100 | 50.0 | 46.9±30.5 | 103 (66.5) | 52 (33.5) | 8 (5.2) |
| SS (n=48) | 30–100 | 67.5 | 65.3±19.7 | 48 (100.0) | 0 | 0 |
| No SS (n=107) | 0–90 | 30.0 | 38.7±31.0 | 55 (51.4) | 52 (48.6) | 8 (7.5) |
| % p16INK4a + cells | 0–100 | 30.0 | 38.5±38.3 | 78 (50.3) | 77 (49.7) | 41 (26.5) |
| SS (n=48) | 0–100 | 62.5 | 58.8±33.8 | 39 (81.3) | 9 (18.8) | 5 (10.4) |
| No SS (n=107) | 0–100 | 10.0 | 29.4±36.8 | 39 (36.4) | 68 (63.6) | 36 (33.6) |
| % p21WAF1/Cip1 + cells | 0–90 | 20.0 | 28.1±26.9 | 61 (39.4) | 94 (60.6) | 14 (9.0) |
| SS (n=48) | 0–90 | 30.0 | 38.2±28.9 | 25 (52.1) | 23 (47.9) | 2 (4.2) |
| No SS (n=107) | 0–90 | 15.0 | 23.5±24.8 | 36 (33.6) | 71 (66.4) | 12 (11.2) |
| % Ki67 + cells | 0–95 | 17.5 | 28.2±25.4 | 60 (38.7) | 95 (61.3) | 3 (1.9) |
| SS (n=48) | 0–28 | 8.3 | 10.2±7.9 | 0 | 48 (100.0) | 2 (4.2) |
| No SS (n=107) | 0–95 | 35.0 | 36.2±26.4 | 60 (56.1) | 47 (43.9) | 1 (0.9) |
High expression: ≥30% NSCLC cells positive; low expression: <30% NSCLC cells positive. SS, senescence signature; SD, standard deviation; NSCLC, non-small cell lung cancer.